An Illustrated Review of Hemophilia B.

Click here for the illustrated open-access review, Hermans C, Astermark J, Trakymienė SŠ, Jiménez-Yuste, V. Haemophilia B: an illustrative review of current challenges and opportunities. Res Prac Thromb Haemostasis, 2025;9, 103229. Abstract Background Hemophilia B is a genetic bleeding disorder caused by a deficiency of clotting factor IX, which presents unique challenges in clinical management. […]

Comments (0)

Bleeding Disorders

Nov 19 2025

george

VWF Factor Assays in Caplacizumab Therapy

Check with your medical library or join ISTH to obtain Colpani P, Baronciani L, Mancini I, et al. Evaluation of different platelet-dependent von Willebrand factor activity assays to assess the in vivo inhibitory effect of caplacizumab on the von Willebrand factor-platelet interaction. J Thromb Haemost. 2025:S1538-7836(25)00545-8. doi: 10.1016/j.jtha.2025.08.020. PMID: 40915571. Abstract Background: Caplacizumab, a humanized […]

Bleeding Disorders

A Case Study: Congenital Hypofibrinogenemia

Check your medical library for Wu Y, Qin K, Xiang L, et al. Congenital hypofibrinogenemia with bleeding risk: mutations in the FGA, FGB, and FGG genes. Lab Med. 2025:lmaf042. doi: 10.1093/labmed/lmaf042. PMID: 41233956. Abstract Introduction: Congenital hypofibrinogenemia is a genetic disorder caused by defects in the fibrinogen gene. We identified a case of congenital hypofibrinogenemia […]

Bleeding Disorders

PBI President Empey Welcomes NBD Foundation President

Fritsma Factor’s George A. Fritsma is pleased to feature Precision BioLogic Inc. (PBI) President and CEO Paul Empey (on the right). Paul is a board member of the National Bleeding Disorders Foundation (NBDF, formerly the National Hemophilia Foundation). On Thursday, November 13, 2025, PBI welcomed Philip Gattone, President & CEO of NBDF. Mr. Gattone toured […]

Bleeding Disorders

Gene Transfer Therapy Updates

Yesterday, 10-28-25, we reported BioMarin’s press release announcing divestiture of their hemophilia A gene transfer therapy, valoctocogene roxaparvovec (Roctavian®). Previously, on February 25, 2025, Pfizer announced their intention to discontinue hemophilia B gene transfer therapy, fidanacogene elaparvovec-dzkt (Becvez®). Press releases from both indicate underperformance in sales. The remaining hemophilia B therapy, etranacogene dezaparvovec-drlb (HEMGENIX®), CSL […]

Bleeding Disorders

BioMarin Plans to Divest Struggling Gene Therapy

Thanks to Dean Willett of Precision BioLogic Inc. for the heads-up on BioMarin’s 10-27-25 post announcing their divestment of the hemophilia A gene transfer therapy, Roctavian. See BioMarin’s 10-27 press release.

Bleeding Disorders

The Blood Project: TTP Module

Click here for a comprehensive review of TTP. This is a segment within The Blood Project, a not-for-profit organization committed to advancing medical knowledge about the crucial role of blood in human health, disease, and therapeutics. TBP offers open-access, web-based, and expertly curated learning tools and resources with the following goals: Enhance Hematological Knowledge: TBP […]

Bleeding Disorders

Precision BioLogic Webinar: Advancing Hemophilia A Testing with a Bovine Chromogenic FVIII Assay

Listen as Precision BioLogic’s Chief Scientific Officer F. Jon Geske, PhD and Marketing Director Ian Burns chair the webinar, Advancing Hemophilia A Testing with a Bovine Chromogenic FVIII Assay. Joining them are… Tara Quinton, R&D Scientist and part of Precision BioLogic’s Chromogenic FVIII assay design team, discussing the assay’s expanded utility along with new data […]

Bleeding Disorders

Activated Protein Complex Concentrate in Emicizumab Prophylaxis

Here is a current open-access review describing APCC usage in emicizumab therapy: Sidonio RF Jr, Young G, Escuriola Ettingshausen C, et al. Activated prothrombin complex concentrate in patients receiving emicizumab prophylaxis: from evidence to clinical practice. Res Pract Thromb Haemost. 2025;9:102926. doi: 10.1016/j.rpth.2025.102926. PMID: 40808796; PMCID: PMC12346059. Abstract Nonfactor therapies (NFTs) such as emicizumab are increasingly […]

Bleeding Disorders

University of Kansas Article About TTP

Here is an editorial review article about TTP that appears in the Spring-Summer edition of the University of Kansas “Kansas Medicine” magazine, entitled “In Their Blood.” The article features X. Long Zheng, MD, PhD, KU pathology head, who provided our January 6, 2021 webinar, “von Willebrand Factor, Friend or Foe?“

Comments (0)

Bleeding Disorders

Bleeding Disorders

An Illustrated Review of Hemophilia B.

VWF Factor Assays in Caplacizumab Therapy

A Case Study: Congenital Hypofibrinogenemia

PBI President Empey Welcomes NBD Foundation President

Gene Transfer Therapy Updates

BioMarin Plans to Divest Struggling Gene Therapy

The Blood Project: TTP Module

Precision BioLogic Webinar: Advancing Hemophilia A Testing with a Bovine Chromogenic FVIII Assay

Activated Protein Complex Concentrate in Emicizumab Prophylaxis

University of Kansas Article About TTP

George Fritsma MS MLS

Cheat Sheets from George

Questions or Comments?

Quick Question